Le Lézard
Classified in: Health
Subject: IMA

Zylox-Tonbridge Receives Marketing Approvals for Multiple Products in the UAE


HANGZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK), a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in the United Arab Emirates for five of its advanced products. These include the ZENFluxiontm Drug-coated PTA Balloon Catheter, ZENFlowtm HP PTA Balloon Catheter, ZENFlowtm PTA Balloon Catheter, ZENFlextm Peripheral Stent System, and ZENFLEX Protm Peripheral Drug-eluting Stent System. This milestone marks Zylox-Tonbridge's first market approval in the Gulf region, demonstrating its dedication to expanding its market presence in the Middle East and advancing global business initiatives.

Zylox-Tonbridge has experienced rapid international growth as a provider of innovative medical solutions. With a comprehensive product portfolio focusing on peripheral vascular and neurovascular interventions, the company is committed to delivering pioneering products and total healthcare solutions worldwide. Its products are currently available in over 20 countries and regions, earning widespread recognition for their innovative designs and high quality.

Driven by economic growth and demographic trends, the Middle East has emerged as a pivotal overseas market for Chinese medical device companies. Recognizing this opportunity, Zylox-Tonbridge consistently showcases its offerings at events like the Arab Health Exhibition, solidifying its position in both regional and global markets. Additionally, with the establishment of its warehouse and logistics center in Italy, the company aims to better serve healthcare providers and patients across Europe, the Middle East, and Africa. The approval of these five Zylox-Tonbridge products in the UAE is expected to fuel growth in Middle Eastern markets, providing local patients with high-quality, affordable, and innovative medical devices.

About Zylox-Tonbridge:
Zylox-Tonbridge is one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China. The Company was founded in 2012 and is headquartered in Hangzhou, China.

As an integrated medical device company supported by our in-house R&D and manufacturing capabilities, proprietary technological platforms, and commercialization capabilities, we strive to provide patients with high-quality and affordable medical devices and services, so that everyone has access to the high-quality life brought by advanced medical technology.

For more information, please visit our official website: www.zyloxtb.com 

 

SOURCE ZYLOX-TONBRIDGE


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: